Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Zhiying Li, Jinlong Tian, Zhen Cheng, Wei Teng, Weijia Zhang, Yiwen Bao, Yidi Wang, Baoge Song, Yi Chen & Bin Li. (2023) Hypoglycemic bioactivity of anthocyanins: A review on proposed targets and potential signaling pathways. Critical Reviews in Food Science and Nutrition 63:26, pages 7878-7895.
Read now
Read now
André J. Scheen. (2023) The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Expert Review of Endocrinology & Metabolism 18:4, pages 271-282.
Read now
Read now
Abraham Edgar Gracia-Ramos, Juana Carretero-Gómez, Carlos E. Mendez & Francisco Javier Carrasco-Sánchez. (2022) Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients. Current Medical Research and Opinion 38:1, pages 43-53.
Read now
Read now
Chan Li & Zhaoya Liu. (2021) Bioinformatic Analysis for Potential Biomarkers and Therapeutic Targets of T2DM-related MI. International Journal of General Medicine 14, pages 4337-4347.
Read now
Read now
André J Scheen. (2020) Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Expert Opinion on Drug Safety 19:3, pages 243-256.
Read now
Read now
Articles from other publishers (46)
Li Ding, Shang Liu, Hao Yan, Zhenyuan Li, Yijun Zhou, Huihua Pang, Renhua Lu, Weiming Zhang, Miaolin Che, Lin Wang, Qin Wang, Wei Fang, Minfang Zhang, Xiajing Che & Leyi Gu. (2023) Pharmacokinetics of Henagliflozin in Dialysis Patients with Diabetes. Clinical Pharmacokinetics 62:11, pages 1581-1587.
Crossref
Crossref
Zejia WuXuyu HeShuang XiaXiaoju XiaoJiyan ChenLiwen Li. (2023) Relationship between dapagliflozin and urinary albumin-to-creatinine ratio in patients with diabetes mellitus and cardiovascular disease: an observational study. Cardiology Plus 8:4, pages 263-268.
Crossref
Crossref
Nishant Johri, Prithpal Sing Matreja, Davis John, Shubham Dutta, Ashok Kumar Parida & Susanta Nath Sarma. (2023) Influence of SGLT2 Inhibitors in Remodeling, Substrate and Ion Metabolism
of Myocardium to Prevent Cardiovascular Risks: Recent Work and
Advancement. Current Molecular Pharmacology 16:5.
Crossref
Crossref
Ivonne Loeffler & Nadja Ziller. (2023) Sex-Related Aspects in Diabetic Kidney Disease—An Update. Journal of Clinical Medicine 12:8, pages 2834.
Crossref
Crossref
Jaime A Davidson, Norlela Sukor, Fen‐Lee Hew, Mafauzy Mohamed & Zanariah Hussein. (2022)
Safety of sodium–glucose c
otransporter
2 inhibitors in Asian type 2 diabetes populations
. Journal of Diabetes Investigation 14:2, pages 167-182.
Crossref
Crossref
Suiyuan Hu, Chu Lin, Xiaoling Cai, Xingyun Zhu, Fang Lv, Wenjia Yang & Linong Ji. (2022) Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology 13.
Crossref
Crossref
Manisha Totade & Shilpa A Gaidhane. (2022) Role of Ertugliflozin in the Management of Diabetes Mellitus. Cureus.
Crossref
Crossref
Ahmed Hamden Al-Jedai, Hajer Yousef Almudaiheem, Dema Abdulrahman Alissa, Hadi Saeed Al-Enazy, Ghazwa B. Korayem, Ahlam Alghamdi & Shabab Alghamdi. (2022) Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A retrospective analysis of claims database. PLOS ONE 17:10, pages e0273836.
Crossref
Crossref
Mohammad Saeedi, Fatemeh Mehranfar, Fateme Ghorbani, Mohammadali Eskandari, Majid Ghorbani & Ali Babaeizad. (2022) Review of Pharmaceutical and Therapeutic Approaches for Type 2 Diabetes and Related Disorders. Recent Patents on Biotechnology 16:3, pages 188-213.
Crossref
Crossref
Tutul Chowdhury, Nicole Gousy, Amulya Bellamkonda, Jui Dutta, Chowdhury F Zaman, Ummul B Zakia, Tasniem Tasha, Priyata Dutta, Padmaja Deb Roy, Adriana M Gomez & Arjun Mainali. (2022) Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy. Cureus.
Crossref
Crossref
B. M. Williams, C. L. Cliff, K. Lee, P. E. Squires & C. E. Hills. (2022) The Role of the NLRP3 Inflammasome in Mediating Glomerular and Tubular Injury in Diabetic Nephropathy. Frontiers in Physiology 13.
Crossref
Crossref
Hoda Gad, Noor Al‐Nassr, Ibrahim Mohammed, Adnan Khan, Ross MacDonald, Paul Mussleman & Rayaz A. Malik. (2022) Effect of Ramadan fasting in patients with type 2 diabetes mellitus treated with sodium–glucose cotransporter 2 inhibitors: A systematic review and meta‐analysis. Journal of Diabetes Investigation 13:5, pages 822-829.
Crossref
Crossref
Wanfang Zheng, Linghuan Li & Hanbing Li. (2022) Phytochemicals modulate pancreatic islet β cell function through glucagon-like peptide-1-related mechanisms. Biochemical Pharmacology 197, pages 114817.
Crossref
Crossref
Suiyuan Hu, Chu Lin, Xiaoling Cai, Xingyun Zhu, Fang Lv, Lin Nie & Linong Ji. (2022) The Urinary Glucose Excretion by Sodium–Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology 12.
Crossref
Crossref
S. Kosirova, D. Rubintova, J. Lacka, J. Klimas, T. Foltanova & I. Tumova. (2022) The Evaluation of Cardiovascular Risk in Diabetic Patients. European Pharmaceutical Journal 69:1, pages 1-8.
Crossref
Crossref
Mariana Tilinca, Robert Tiuca, Ioan Tilea & Andreea Varga. (2021) The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. Journal of Personalized Medicine 11:12, pages 1249.
Crossref
Crossref
Dragan B. Djordjevic, Goran Koracevic, Aleksandar D. Djordjevic & Dragan B. Lovic. (2021) Diabetic Cardiomyopathy: Clinical and Metabolic Approach. Current Vascular Pharmacology 19:5, pages 487-498.
Crossref
Crossref
Johannes F. E. Mann, John B. Buse, Thomas Idorn, Lawrence A. Leiter, Richard E. Pratley, Søren Rasmussen, Tina Vilsbøll, Benjamin Wolthers & Vlado Perkovic. (2021) Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes, Obesity and Metabolism 23:9, pages 2058-2066.
Crossref
Crossref
Dan Xu, Owain Chandler, Cleo Wee, Chau Ho, Jacquita S. Affandi, Daya Yang, Xinxue Liao, Wei Chen, Yanbing Li, Christopher Reid & Haipeng Xiao. (2021) Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?. Frontiers in Medicine 8.
Crossref
Crossref
Lale A. Ertuglu, Esteban Porrini, Mads Hornum, Atalay Demiray, Baris Afsar, Alberto Ortiz, Adrian Covic, Peter Rossing & Mehmet Kanbay. (2021) Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation. Transplant International 34:8, pages 1341-1359.
Crossref
Crossref
Ya. F. Zverev & A. Ya. Rykunova. (2021) Nephroprotective effect of novel oral sugar-reducing medicines: glyflosins. Nephrology (Saint-Petersburg) 25:4, pages 11-22.
Crossref
Crossref
Husam Ghanim, Manav Batra, Kelly Green, Jeanne Hejna, Sanaa Abuaysheh, Antione Makdissi, Ajay Chaudhuri & Paresh Dandona. (2021) Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors. Diabetes, Obesity and Metabolism 23:7, pages 1614-1623.
Crossref
Crossref
Leandro Fernández-Fernández, Alfonso Barquilla-García, Javier Sánchez-Vega, José Carlos Risco-Solanilla, Félix Suárez-González & Francisco Buitrago. (2021) Prevalence of Chronic Kidney Disease in Patients with Diabetes in Extremadura (Spain) during the Years 2012, 2013 and 2014: An Observational Study. Journal of Clinical Medicine 10:13, pages 2886.
Crossref
Crossref
Yi-Suk Kim, Yong-Moon Park, Kyung-Do Han, Jae-Seung Yun, Yu-Bae Ahn & Seung-Hyun Ko. (2021) Fasting glucose level and all-cause or cause-specific mortality in Korean adults: a nationwide cohort study. The Korean Journal of Internal Medicine 36:3, pages 647-658.
Crossref
Crossref
W. David Strain, Su Down, Pam Brown, Amar Puttanna & Alan Sinclair. (2021) Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes. Diabetes Therapy 12:5, pages 1227-1247.
Crossref
Crossref
Donald S. Nelinson, Jose M. Sosa & Robert J. Chilton. (2021) SGLT2 inhibitors: a narrative review of efficacy and safety. Journal of Osteopathic Medicine 121:2, pages 229-239.
Crossref
Crossref
Wanning Wang, Jia Li & Lu Cai. (2021) Research progress of sirtuins in renal and cardiovascular diseases. Current Opinion in Nephrology & Hypertension 30:1, pages 108-114.
Crossref
Crossref
Zhendong Chen, Liang Li, Yan Zhan, Yifan Zhang, Haiyan Liu, Jianjun Zou & Dafang Zhong. (2021) Characterization and quantitative determination of henagliflozin metabolites in humans. Journal of Pharmaceutical and Biomedical Analysis 192, pages 113632.
Crossref
Crossref
Vadim V Klimontov, Anton I Korbut, Iuliia S Taskaeva, Nataliya P Bgatova, Maksim V Dashkin, Nikolai B Orlov, Anna S Khotskina, Evgenii L Zavyalov & Thomas Klein. (2020)
Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in
db/db
diabetic mice
. World Journal of Diabetes 11:12, pages 596-610.
Crossref
Crossref
Lihua Ni, Cheng Yuan, Guopeng Chen, Changjiang Zhang & Xiaoyan Wu. (2020) SGLT2i: beyond the glucose-lowering effect. Cardiovascular Diabetology 19:1.
Crossref
Crossref
André J. Scheen. (2020) Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology 16:10, pages 556-577.
Crossref
Crossref
Salem A. Beshyah, Khadija Hafidh & Tariq Gul Shaikh. (2020) Evolving physicians’ perceptions and practices regarding use of SGLT2 inhibitors for type 2 diabetes during Ramadan fasting. Diabetes Research and Clinical Practice 168, pages 108389.
Crossref
Crossref
William P. Martin, Colm Tuohy, Alison Doody, Sabrina Jackson, Ronan J. Canavan, David Slattery, Patrick J. Twomey, Malachi J. McKenna, Carel W. le Roux & Neil G. Docherty. (2020) Parallel assessment of albuminuria and plasma sTNFR1 in people with type 2 diabetes and advanced chronic kidney disease provides accurate prognostication of the risks of renal decline and death. Scientific Reports 10:1.
Crossref
Crossref
Rawan Amir, Sara Suhl & Charles M. Alexander. (2020) Renal Evaluation and Protection. Clinics in Geriatric Medicine 36:3, pages 431-445.
Crossref
Crossref
André J. Scheen. (2020) Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacokinetics 59:8, pages 981-994.
Crossref
Crossref
Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Ryusuke Koshida, Hiroyuki Kameda, Masahiro Tamura & Kohei Kaku. (2020) Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT). Journal of Diabetes Investigation 11:4, pages 906-916.
Crossref
Crossref
Guntram Schernthaner, Per‐Henrik Groop, Philip A. Kalra, Claudio Ronco & Maarten W. Taal. (2020) Sodium‐glucose linked transporter‐2 inhibitor renal outcome modification in type 2 diabetes: Evidence from studies in patients with high or low renal risk. Diabetes, Obesity and Metabolism 22:7, pages 1024-1034.
Crossref
Crossref
Uwe Querfeld, Robert H. Mak & Axel Radlach Pries. (2020) Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity. Clinical Science 134:12, pages 1333-1356.
Crossref
Crossref
Sumanta Saha & Sujata Saha. (2020) The comparison of efficacy and safety between different doses of empagliflozin in insulin-treated type 1 diabetes mellitus patients: a systematic review and meta-analysis protocol. Journal of Diabetes & Metabolic Disorders 19:1, pages 545-550.
Crossref
Crossref
Cosmin Mihai Vesa, Loredana Popa, Amorin Remus Popa, Marius Rus, Andreea Atena Zaha, Simona Bungau, Delia Mirela Tit, Raluca Anca Corb Aron & Dana Carmen Zaha. (2020) Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors. Diagnostics 10:5, pages 314.
Crossref
Crossref
Erika F. Gómez-García, Laura Cortés-Sanabria, Alfonso M. Cueto-Manzano, R. Susana Medina-Zavala, Luis Eduardo Hernández-Ramos, Héctor Ramón Martínez-Ramírez, José Clemente Vásquez-Jiménez & Francisco Mendoza-Carrera. (2020) Interactions Between Diet Quality and Interleukin-6 Genotypes Are Associated With Metabolic and Renal Function Parameters in Mexican Patients With Type 2 Diabetes Mellitus. Journal of Renal Nutrition 30:3, pages 223-231.
Crossref
Crossref
I. Löffler & G. Wolf. (2020) Geschlechtsunterschiede bei der diabetischen NephropathieSex differences in diabetic nephropathy. Der Nephrologe 15:3, pages 136-144.
Crossref
Crossref
Wenting Liu, Xiaowen Chen, Yuxian Wang, Yihua Chen, Sijia Chen, Wangqiu Gong, Ting Chen, Lingzhi Sun, Chenghao Zheng, Bohui Yin, Shuting Li, Congwei Luo, Qianyin Huang, Jing Xiao, Zhaozhong Xu, Fenfen Peng & Haibo Long. (2019) Micheliolide ameliorates diabetic kidney disease by inhibiting Mtdh-mediated renal inflammation in type 2 diabetic db/db mice. Pharmacological Research 150, pages 104506.
Crossref
Crossref
Kohei Omachi & Jeffrey H. Miner. (2019) Alport Syndrome Therapeutics: Ready for Prime-Time Players. Trends in Pharmacological Sciences 40:11, pages 803-806.
Crossref
Crossref
Barbara Bonino, Giovanna Leoncini, Salvatore De Cosmo, Eulalia Greco, Giuseppina T. Russo, Annalisa Giandalia, Francesca Viazzi & Roberto Pontremoli. (2019) Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach. Medicina 55:7, pages 382.
Crossref
Crossref
Sumanta Saha & Sujata Saha. (2019) A Systematic Review and Meta-Analysis of Randomised Controlled Trials, Contrasting the Safety Profile between Sodium-Glucose Cotransporter-2 Inhibitors and Placebo in Type 1 Diabetes Mellitus Patients. Dubai Diabetes and Endocrinology Journal 25:3-4, pages 62-73.
Crossref
Crossref